Press "Enter" to skip to content

Jubilant Life: New Covid drug, worth unlocking potential to result in upside

Shares of Jubilant Life Sciences, which scaled a 52-week excessive on Wednesday, are up over 200 per cent since March lows.

Strong prospects in each, its prescription drugs and Life Sciences Ingredients (LSI) segments led by the specialty enterprise, settlement with Gilead Sciences Inc for the home launch of Covid-19 remedy drug Remdesivir, recovering provides of lively components and others put up lockdown, and a robust March quarter efficiency, have boosted Street sentiment. While future prospects stay good, the corporate’s plan of demerging its prescription drugs and LSI segments may …

Be First to Comment

    Leave a Reply